title: Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
abstract: Simian immunodeficiency virus (SIV) infection of rhesus macaques provides an excellent model for investigating the basis of protective immunity against human immunodeficiency virus (HIV). One limitation of this model, however, has been the availability of a small number of known MHC class I-restricted CTL epitopes for investigating virus-specific immune responses. We assessed CTL responses against SIV Gag in a cohort of DNA/modified vaccinia virus Ankara (MVA)-vaccinated/simian-human immunodeficiency virus (SHIV)-challenged rhesus macaques. Here, we report the identification of five novel SIV CTL epitopes in Gag for the first time (Gag(39-46) NELDRFGL, Gag(169-177) EVVPGFQAL, Gag(198-206) AAMQIIRDI, Gag(257-265) IPVGNIYRR and Gag(296-305) SYVDRFYKSL) that are restricted by the common MHC class I molecule Mamu-B*01. CTL responses to these epitopes were readily detected in cryopreserved PBMC in multiple animals up to 62 weeks post-infection, both by IFN-gamma enzyme-linked immunospot assay and intracellular IFN-gamma staining. Importantly, viral sequencing results revealed that these epitopes are highly conserved in the SIV-challenged macaques over a long period of time, indicating functional constraints in these regions. Moreover, the presence of CTL responses targeting these epitopes has been confirmed in two independent cohorts of rhesus macaques that have been challenged by SHIV or SIV. Our findings provide valuable candidates for poly-epitope vaccines and for long-term quantitative monitoring of epitope-specific CD8(+) responses in the context of this common Mamu class I allele. It may thus help increase the supply of rhesus macaques in which epitope-specific immunity can be studied in the context of SIV vaccine design.
authors.affiliation: Department of Medicine, University of Toronto, Toronto, Canada.
authors.forename: Jin
authors.initials: J
authors.lastname: Su
authors.forename: Mark A
authors.initials: MA
authors.lastname: Luscher
authors.forename: Yelin
authors.initials: Y
authors.lastname: Xiong
authors.forename: Tarick
authors.initials: T
authors.lastname: Rustam
authors.forename: Rama Rao
authors.initials: RR
authors.lastname: Amara
authors.forename: Eva
authors.initials: E
authors.lastname: Rakasz
authors.forename: Harriet L
authors.initials: HL
authors.lastname: Robinson
authors.forename: Kelly S
authors.initials: KS
authors.lastname: MacDonald
mesh_terms: D000818:Animals; D018604:Epitope Mapping; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D015750:Genes, gag; D005838:Genotype; D006678:HIV / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D007371:Interferon-gamma / Q000096:biosynthesis; D008253:Macaca mulatta; D012313:RNA / Q000378:metabolism; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology
chemical_list: D018984:Epitopes, T-Lymphocyte; D015395:Histocompatibility Antigens Class I; C089390:Mamu-A 02 antigen; C092249:Mamu-B 01 antigen, Macaca mulatta; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D012313:RNA; D007371:Interferon-gamma